Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
Open Access
- 20 July 2020
- Vol. 12 (7), 1988
- https://doi.org/10.3390/cancers12071988
Abstract
Pancreatic neuroendocrine tumours (PanNETs) are rare diseases and a good example of how research is not only feasible, but also of crucial importance in the scenario of rare tumours. Many clinical trials have been performed over the past two decades expanding therapeutic options for patients with advanced PanNETs. Adequate management relies on optimal selection of treatment, which may be challenging for clinicians due to the fact that multiple options of therapy are currently available. A number of therapies already exist, which are supported by data from phase III studies, including somatostatin analogues and targeted therapies (sunitinib and everolimus). In addition, chemotherapy remains an option, with temozolomide and capecitabine being one of the most popular doublets to use. Peptide receptor radionuclide therapy was successfully implemented in patients with well-differentiated gastro-entero-pancreatic neuroendocrine tumours, but with certain questions waiting to be solved for the management of PanNETs. Finally, the role of immunotherapy is still poorly understood. In this review, the data supporting current systemic treatment options for locally advanced or metastatic PanNETs are summarized. Strategies for treatment selection in patients with PanNETs based on patient, disease, or drug characteristics is provided, as well as a summary of current evidence on prognostic and predictive biomarkers. Future perspectives are discussed, focusing on current and forthcoming challenges and unmet needs of patients with these rare tumours.This publication has 145 references indexed in Scilit:
- Update on the Role of Somatostatin Analogs for the Treatment of Patients With Gastroenteropancreatic Neuroendocrine TumorsSeminars in Oncology, 2013
- Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumoursEndocrine-Related Cancer, 2012
- Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)European Journal of Nuclear Medicine and Molecular Imaging, 2011
- Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)Annals of Oncology, 2010
- Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumoursBritish Journal of Cancer, 2010
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II StudyJournal of Clinical Oncology, 2008
- The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal CancerThe Oncologist, 2007
- The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option?European Journal of Cancer, 2004
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- Interferon in the Management of Neuroendocrine GEP-TumorsDigestion, 2000